Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, double-blind, placebo-controlled study to assess the safety, tolerability and effect of taspoglutide on glycemic control compared to placebo in patients with type II diabetes mellitus inadequately controlled with metformin plus pioglitazone.

Next Previous
Search
Trial Profile

A multicenter, randomized, double-blind, placebo-controlled study to assess the safety, tolerability and effect of taspoglutide on glycemic control compared to placebo in patients with type II diabetes mellitus inadequately controlled with metformin plus pioglitazone.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Taspoglutide (Primary) ; Metformin; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms T-EMERGE-3
  • Sponsors Roche

    • Most Recent Events

    • 06 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Jul 2012 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
    • 26 Apr 2012 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met according to results published in the Journal of Clinical Endocrinology and Metabolism.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top